Diplomat Pharmacy Inc (NYSE:DPLO) Director Jeffrey G. Park sold 1,695 shares of the business’s stock in a transaction that occurred on Monday, June 11th. The stock was sold at an average price of $25.26, for a total transaction of $42,815.70. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Jeffrey G. Park also recently made the following trade(s):
- On Wednesday, May 23rd, Jeffrey G. Park sold 13,875 shares of Diplomat Pharmacy stock. The shares were sold at an average price of $24.20, for a total transaction of $335,775.00.
Shares of Diplomat Pharmacy traded up $0.57, hitting $26.98, during trading hours on Thursday, according to MarketBeat Ratings. The stock had a trading volume of 713,857 shares, compared to its average volume of 890,107. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.88 and a quick ratio of 0.57. Diplomat Pharmacy Inc has a fifty-two week low of $14.23 and a fifty-two week high of $27.78. The stock has a market cap of $1.90 billion, a P/E ratio of 32.12 and a beta of 1.33.
Institutional investors and hedge funds have recently bought and sold shares of the stock. SG Americas Securities LLC acquired a new position in shares of Diplomat Pharmacy in the 1st quarter valued at $104,000. Meadow Creek Investment Management LLC acquired a new position in shares of Diplomat Pharmacy in the 1st quarter valued at $107,000. Glen Harbor Capital Management LLC acquired a new position in shares of Diplomat Pharmacy in the 1st quarter valued at $129,000. Advisors Preferred LLC acquired a new position in shares of Diplomat Pharmacy in the 4th quarter valued at $162,000. Finally, UBS Group AG lifted its stake in shares of Diplomat Pharmacy by 186.4% in the 1st quarter. UBS Group AG now owns 8,491 shares of the company’s stock valued at $171,000 after purchasing an additional 5,526 shares during the period. Hedge funds and other institutional investors own 75.92% of the company’s stock.
DPLO has been the subject of several research reports. Zacks Investment Research cut shares of Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research note on Tuesday, May 1st. Barclays initiated coverage on shares of Diplomat Pharmacy in a research note on Thursday, March 8th. They set an “overweight” rating and a $27.00 price objective for the company. Leerink Swann set a $30.00 price objective on shares of Diplomat Pharmacy and gave the company a “buy” rating in a research note on Tuesday, February 27th. Deutsche Bank upgraded shares of Diplomat Pharmacy from a “hold” rating to a “buy” rating in a research note on Friday, March 2nd. Finally, Needham & Company LLC set a $28.00 price objective on shares of Diplomat Pharmacy and gave the company a “buy” rating in a research note on Tuesday, February 27th. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $26.90.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.